John Primrose
A5007992268- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- MicroRNA in disease regulation
- Colorectal Cancer Surgical Treatments
- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Circular RNAs in diseases
- Gallbladder and Bile Duct Disorders
- Helicobacter pylori-related gastroenterology studies
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Cardiac, Anesthesia and Surgical Outcomes
- Liver Disease Diagnosis and Treatment
- Cancer Cells and Metastasis
- Pancreatitis Pathology and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Esophageal Cancer Research and Treatment
- Enhanced Recovery After Surgery
- Liver physiology and pathology
- Cancer-related molecular mechanisms research
University of Southampton
2016-2025
NIHR Southampton Biomedical Research Centre
2014-2025
University Hospital Southampton NHS Foundation Trust
2016-2025
Fondazione Poliambulanza Istituto Ospedaliero
2024
Southampton General Hospital
2012-2023
Hôpital Beaujon
2023
Assistance Publique – Hôpitaux de Paris
2023
Cancer Research UK Clinical Trials Unit
2011-2022
University College London
2011-2022
Bristol-Myers Squibb (Switzerland)
2022
Background: Hepatic metastases develop in approximately 50% of colorectal cancer (CRC) cases. We performed a review and meta-analysis to evaluate survival after resection CRC liver (CLMs) estimated the summary effect for seven prognostic factors. Methods: Studies published between 1999 2010, indexed on Medline, that reported CLMs, were reviewed. Meta-relative risks by factor calculated, stratified study size annual clinic volume. Cumulative results volume plotted. Results: Five- 10-year...
The European Guidelines Meeting on Laparoscopic Liver Surgery was held in Southampton February 10 and 11, 2017 with the aim of presenting validating clinical practice guidelines for laparoscopic liver surgery.
BackgroundTransarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while multikinase inhibitor sorafenib improves survival in advanced disease. We aimed to determine whether TACE progression-free versus placebo.MethodsWe did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) 20 hospitals UK unresectable, liver-confined carcinoma. Patients were eligible if they at least aged 18 years, had Eastern...
IMPORTANCEIntensive follow-up after surgery for colorectal cancer is common practice but based on limited evidence.OBJECTIVE To assess the effect of scheduled blood measurement carcinoembryonic antigen (CEA) and computed tomography (CT) as to detect recurrent treatable with curative intent.DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial in 39 National Health Service hospitals United Kingdom; 1202 eligible participants were recruited between January 2003 August 2009 who had...
Human papillomavirus (HPV)-positive oropharyngeal cancer (OPSCC) is associated with improved survival compared HPV-negative disease. However, a minority of HPV-positive patients have poor prognosis. Currently, there no generally accepted strategy for identifying these patients. We retrospectively analysed 270 consecutively treated OPSCC from three centres effects clinical, pathological, immunological, and molecular features on disease mortality. used Cox regression to examine associations...
Objective: The aim of this study was to compare oncological outcomes after minimally invasive distal pancreatectomy (MIDP) with open (ODP) in patients pancreatic ductal adenocarcinoma (PDAC). Background: Cohort studies have suggested superior short-term MIDP vs. ODP. Recent international surveys, however, revealed that surgeons concerns about the for PDAC. Methods: This is a pan-European propensity score matched including who underwent (laparoscopic or robot-assisted) ODP PDAC between...
Despite complete resection, disease-free survival (DFS) of patients with cholangiocarcinoma (CCA) is less than 65 % after one year and not more 35 three years. For muscle invasive gallbladder carcinoma (GBCA), prognosis even worse, an overall (OS) only 30 Thus, evaluation adjuvant chemotherapy in biliary tract cancer a large randomized trial warranted.
BackgroundThe interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction progression-free survival allocated to cetuximab plus chemotherapy compared those given alone. The focus present was assess effect on overall survival.MethodsNew multicentre, open-label, randomised, controlled, phase 3 trial. Adult (aged ≥18 years) KRAS wild-type (codons 12, 13, and 61) or suboptimally metastases WHO performance status 0–2...
4006 Background: Despite improvements in multidisciplinary management, BTC has a poor outcome. Approximately 20% of cases are suitable for surgical resection with 5 year survival < 10%. BILCAP aimed to determine whether capecitabine (Cape) improves overall (OS) compared observation (Obs) following radical surgery. Methods: Patients completely-resected cholangiocarcinoma (CCA) or gallbladder cancer (including liver and pancreatic resection, as appropriate), adequate biliary drainage, no...
PURPOSE The BILCAP study described a modest benefit for capecitabine as adjuvant therapy curatively resected biliary tract cancer (BTC), and has become the standard of care. We present long-term data novel exploratory subgroup analyses. METHODS This randomized, controlled, multicenter, phase III recruited patients age 18 years or older with histologically confirmed cholangiocarcinoma muscle-invasive gallbladder after resection curative intent an Eastern Cooperative Oncology Group performance...
The oncological safety of minimally invasive surgery has been questioned for several abdominal cancers. Concerns also exist regarding the use distal pancreatectomy (MIDP) in patients with resectable pancreatic cancer as randomised trials are lacking.In this international non-inferiority trial, we recruited adults from 35 centres 12 countries. Patients were randomly assigned to either MIDP (laparoscopic or robotic) open (ODP). Both and pathologists blinded approach. Primary endpoint was...
Objective: To develop and update evidence- consensus-based guidelines on laparoscopic robotic pancreatic surgery. Summary Background Data: Minimally invasive surgery (MIPS), including surgery, is complex technically demanding. Minimizing the risk for patients requires stringent, evidence-based guidelines. Since International Miami Guidelines MIPS in 2019, new developments key publications have been reported, necessitating an update. Methods: Evidence-based 22 topics 8 domains were proposed:...
PURPOSE To compare outcomes after laparoscopic versus open major liver resection (hemihepatectomy) mainly for primary or metastatic cancer. The outcome measure was time to functional recovery. Secondary included morbidity, quality of life (QoL), and those with cancer, margin status adjuvant systemic therapy. PATIENTS AND METHODS This a multicenter, randomized controlled, patient-blinded, superiority trial on adult patients undergoing hemihepatectomy. Patients were recruited from 16 hospitals...
Objective: The aim of this study was to compare the perioperative outcomes robotic liver surgery (RLS) and laparoscopic (LLS) in various settings. Summary Background Data: Clear advantages RLS over LLS have rarely been demonstrated, associated costs are generally higher than those surgery. Therefore, exact role approach minimally invasive remains be defined. Methods: In international retrospective cohort study, patients who underwent for all indications between 2009 2021 34 hepatobiliary...